Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients
- PMID: 17047214
- DOI: 10.1001/jama.296.15.1843
Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients
Abstract
Context: Although liberalization of donor criteria could expand the donor pool, the use of certain "marginal donors," such as those who are hepatitis C virus (HCV) positive, is controversial. Little is known about the effect of donor HCV positivity on survival in cardiac transplantation.
Objectives: To examine the association between donor HCV positivity and survival among heart transplant recipients and to determine the effects of recipient age and recipient HCV status on this association.
Design, setting, and participants: A multicenter cohort study was performed using the US Scientific Registry of Transplant Recipients. Adult heart transplant patients who received their transplants between April 1, 1994, and July 31, 2003, were eligible for inclusion.
Main outcome measure: All-cause mortality.
Results: Of 10 915 patients meeting entry criteria, 261 received an HCV-positive donor heart. Mortality was higher among recipients of HCV-positive donor hearts at 1 year (16.9% vs 8.2%; P<.001), 5 years (41.8% vs 18.5%; P<.001), and 10 years (50.6% vs 24.3%; P<.001). Using Kaplan-Meier methods, 1-, 5-, and 10-year survival rates were 83%, 53%, and 25%, and 92%, 77%, and 53% for recipients of HCV-positive and HCV-negative donor hearts, respectively (P<.001, log-rank test). Recipients of HCV-positive donor hearts were more likely to die of liver disease and coronary vasculopathy. After propensity matching, the overall hazard ratio (HR) associated with receipt of an HCV-positive donor heart was 2.10 (95% confidence interval [CI], 1.60-2.75). Stratified analyses showed that HRs did not vary by recipient HCV status or by recipient age (for recipients aged 18-39 years: HR, 1.75 [95% CI, 0.70-4.40]; for recipients aged 40-59 years: HR, 2.23 [95% CI, 1.42-3.52]; and for recipients aged 60 years and older: HR, 2.07 [95% CI, 1.32-3.27]; overall P value for interaction, >.10).
Conclusions: Receipt of a heart from an HCV-positive donor is associated with decreased survival in heart transplant recipients. This association appears to be independent of recipient HCV status and age. Preferential allocation of HCV-positive donors to HCV-positive recipients and/or older recipients is not warranted.
Comment in
-
Poorer outcomes for recipients of heart allografts from HCV-positive donors: opening the silos.JAMA. 2006 Oct 18;296(15):1900-1. doi: 10.1001/jama.296.15.1900. JAMA. 2006. PMID: 17047220 No abstract available.
-
Hepatitis C in organ donors and heart transplant recipients.JAMA. 2007 Feb 21;297(7):696; author reply 696-7. doi: 10.1001/jama.297.7.696-a. JAMA. 2007. PMID: 17312284 No abstract available.
Similar articles
-
Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation.J Heart Lung Transplant. 2004 Mar;23(3):277-83. doi: 10.1016/S1053-2498(03)00148-7. J Heart Lung Transplant. 2004. PMID: 15019636
-
Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999.Clin Transpl. 2003:89-100. Clin Transpl. 2003. PMID: 15387100
-
Impact of donor age on survival after heart transplantation: an analysis of the United Network for Organ Sharing (UNOS) registry.J Card Surg. 2014 Sep;29(5):723-8. doi: 10.1111/jocs.12406. Epub 2014 Jul 19. J Card Surg. 2014. PMID: 25041692
-
Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation.Curr Opin Organ Transplant. 2015 Jun;20(3):267-75. doi: 10.1097/MOT.0000000000000191. Curr Opin Organ Transplant. 2015. PMID: 25944236 Review.
-
Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors.Cardiol Rev. 2019 Jul/Aug;27(4):179-181. doi: 10.1097/CRD.0000000000000255. Cardiol Rev. 2019. PMID: 31180937 Review.
Cited by
-
Revolutionizing Donor Heart Procurement: Innovations and Future Directions for Enhanced Transplantation Outcomes.J Cardiovasc Dev Dis. 2024 Jul 27;11(8):235. doi: 10.3390/jcdd11080235. J Cardiovasc Dev Dis. 2024. PMID: 39195143 Free PMC article. Review.
-
Strategies for Expanding Donors Pool in Heart Transplantation.Rev Cardiovasc Med. 2022 Aug 15;23(8):285. doi: 10.31083/j.rcm2308285. eCollection 2022 Aug. Rev Cardiovasc Med. 2022. PMID: 39076623 Free PMC article. Review.
-
Early Assessment of Cardiac Allograft Vasculopathy Risk Among Recipients of Hepatitis C Virus-infected Donors in the Current Era.J Card Fail. 2024 May;30(5):694-700. doi: 10.1016/j.cardfail.2023.09.015. Epub 2023 Oct 29. J Card Fail. 2024. PMID: 37907147
-
Preemptive antiviral therapy in lung transplantation from hepatitis C donors results in a rapid and sustained virologic response.JTCVS Open. 2023 Mar 10;14:602-614. doi: 10.1016/j.xjon.2023.02.014. eCollection 2023 Jun. JTCVS Open. 2023. PMID: 37425441 Free PMC article. Clinical Trial.
-
Review of heart transplantation from hepatitis C-positive donors.World J Transplant. 2022 Dec 18;12(12):394-404. doi: 10.5500/wjt.v12.i12.394. World J Transplant. 2022. PMID: 36570408 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
